Towards Long-Term Stable Polyimide-Based Flexible Electrical Insulation for Chronically Implanted Neural Electrodes.

For chronic applications of flexible neural implants, e.g., intracortical probes, the flexible substrate material has to encapsulate the electrical conductors with a long-term stability against the saline environment of the neural tissue. The biocompatible polymer polyimide is often used for this purpose. Due to its chemical inertness, the adhesion between two polyimide layers is, however, a challenge, which can lead to delamination and, finally, to short circuits. The state-of-the-art method to improve the adhesion strength is activating the polyimide surface using oxygen reactive ion etching (O2 RIE). However, the influence of the process variations (etching time, bias power) on the long-term stability is still unclear. Therefore, we establish a test method, where the aging of a gold interdigital structure embedded in two polyimide layers and immersed in saline solution is accelerated using an elevated temperature, mechanical stress and an electrical field. A continuous measurement of a leakage current is used to define the failure state. The results show that the variation of the O2 RIE plasma process has a significant effect on the long-term stability of the test samples. Comparing the two different plasma treatments 0.5 min at 25 W and 1 min at 50 W, the long-term stability could be increased from 20.9 ± 19.1 days to 44.9 ± 18.9 days. This corresponds to more than a doubled lifetime. An ideal solution for the delamination problem is still not available; however, the study shows that the fine-tuning of the fabrication processes can improve the long-term stability of chronically implanted neural electrodes.

Quantitative impedimetric NPY-receptor activation monitoring and signal pathway profiling in living cells.

Label-free and non-invasive monitoring of receptor activation and identification of the involved signal pathways in living cells is an ongoing analytic challenge and a great opportunity for biosensoric systems. In this context, we developed an impedance spectroscopy-based system for the activation monitoring of NPY-receptors in living cells. Using an optimized interdigital electrode array for sensitive detection of cellular alterations, we were able for the first time to quantitatively detect the NPY-receptor activation directly without a secondary or enhancer reaction like cAMP-stimulation by forskolin. More strikingly, we could show that the impedimetric based NPY-receptor activation monitoring is not restricted to the Y1-receptor but also possible for the Y2- and Y5-receptor. Furthermore, we could monitor the NPY-receptor activation in different cell lines that natively express NPY-receptors and proof the specificity of the observed impedimetric effect by agonist/antagonist studies in recombinant NPY-receptor expressing cell lines. To clarify the nature of the observed impedimetric effect we performed an equivalent circuit analysis as well as analyzed the role of cell morphology and receptor internalization. Finally, an antagonist based extensive molecular signal pathway analysis revealed small alterations of the actin cytoskeleton as well as the inhibition of at least L-type calcium channels as major reasons for the observed NPY-induced impedance increase. Taken together, our novel impedance spectroscopy based NPY-receptor activation monitoring system offers the opportunity to identify signal pathways as well as for novel versatile agonist/antagonist screening systems for identification of novel therapeutics in the field of obesity and cancer.

Comparative label-free monitoring of immunotoxin efficacy in 2D and 3D mamma carcinoma in vitro models by impedance spectroscopy.

For selective killing of tumor cells, there are many novel and promising therapeutic approaches like immunotoxins. However, on the long way to clinical application, especially in vitro approved biologicals often fail due to loss of target sensitivity and efficacy in vivo. This is mostly explained with degradation or penetration disability in vivo. Although, these problems are well known, until today, there are no in vitro systems for reliable monitoring and quantification of therapeutic efficacy in 3D tumor models and the direct comparison to results from 2D models. In this context, we developed a combined label-free impedimetric monitoring system using our self-developed planar interdigital electrode arrays and our unique microcavity array technology. Therefore, we could demonstrate the time and concentration dependent monitoring and quantification of therapeutic efficacy in a 2D and 3D mamma carcinoma model. In detail, we synthesized a novel modular immunotoxin B3(dsFv)-PE38 (B3-PE38) in which the antibody fragment and the protein toxin are polyionic linked together. We compared the efficacy of the immunotoxin B3-PE38, the toxin E8C-PE38 (PE38) and the small molecule chemotherapeutic paclitaxel. The impedimetric screening revealed the highest cytotoxicity for the immunotoxin B3-PE38 in the 2D model. More strikingly, the immunotoxin efficacy was substantially higher in the 3D model when compared to PE38 and paclitaxel even though having a considerably lower penetration capability than paclitaxel. So our novel impedimetric monitoring system offers the comparative efficacy quantification of novel therapeutics in 2D and 3D in vitro tumor models.